ABPO Abpro Holdings, Inc.
Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1893219 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY119.1%
TTM EPS YoY108.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR-26.1%
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA46.1%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets156.9%
Debt / equity—
Current ratio0.62x
Interest coverage-22.07x
Cash quality & payout
Operating cash flow / net income-3.00x
Accruals ratio184.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY2024*2024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | $183,000 |
| R&D expense | $989,000 | $2.98M |
| SG&A expense | $7.46M | $7.12M |
| Operating income | -$8.45M | -$9.92M |
| Interest expense | $1.13M | $387,000 |
| Pretax income | — | -$7.23M |
| Net income | -$2.89M | -$7.23M |
| EBITDA | -$8.43M | -$9.85M |
| EPS (basic) | -1.30 | -22.31 |
| EPS (diluted) | -1.30 | -22.31 |
| Weighted avg. shares (diluted) | 2.23M | 780,332 |
| Balance sheet | ||
| Cash & equivalents | $82,000 | $2.99M |
| Receivables | $183,000 | $183,000 |
| Current assets | $896,000 | $3.78M |
| PP&E, net | — | $37,000 |
| Total assets | $1.06M | $4.66M |
| Current liabilities | $9.35M | $19.61M |
| Total liabilities | $9.35M | $19.61M |
| Shareholders' equity | -$8.83M | -$15.49M |
| Shares outstanding | 2.73M | 1.69M |
| Cash flow statement | ||
| Operating cash flow | -$6.01M | -$9.03M |
| Financing cash flow | $3.07M | $11.16M |
| Depreciation & amortization | $21,000 | $74,000 |
| Stock-based compensation | $1.49M | $1.93M |
Free plan shows the latest 2 periods; Pro shows all 4 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.